"Janus Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is predominantly expressed in hematopoietic cells. It is involved in signaling from a broad variety of CYTOKINE RECEPTORS including ones that utilize the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT.
| Descriptor ID |
D053616
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.300 D12.776.476.393.300
|
| Concept/Terms |
Janus Kinase 3- Janus Kinase 3
- Kinase 3, Janus
- JAK-3 Protein Tyrosine Kinase
- JAK 3 Protein Tyrosine Kinase
- JAK3 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 3".
This graph shows the total number of publications written about "Janus Kinase 3" by people in this website by year, and whether "Janus Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 3" by people in Profiles.
-
Grant AH, Rodriguez AC, Rodriguez Moncivais OJ, Sun S, Li L, Mohl JE, Leung MY, Kirken RA, Rodriguez G. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling. Int J Mol Sci. 2023 Apr 06; 24(7).
-
Ruiz-Medina BE, Ross JA, Kirken RA. Interleukin-2 Receptor ? Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules. J Biol Chem. 2015 Aug 21; 290(34):20972-20983.
-
Ross JA, Spadaro M, Rosado DC, Cavallo F, Kirken RA, Pericle F. Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. Leukemia. 2014 Apr; 28(4):941-4.
-
Rodriguez G, Ross JA, Nagy ZS, Kirken RA. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex. J Biol Chem. 2013 Mar 08; 288(10):7137-46.
-
Nagy ZS, Ross JA, Rodriguez G, Bader J, Dimmock J, Kirken RA. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways. FEBS Lett. 2010 Apr 16; 584(8):1515-20.
-
Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation. J Biol Chem. 2010 Feb 05; 285(6):3582-3591.
-
Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer. 2009 Aug 26; 8:67.
-
Cheng H, Ross JA, Frost JA, Kirken RA. Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity. Mol Cell Biol. 2008 Apr; 28(7):2271-82.
-
Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood. 2006 Oct 01; 108(7):2407-15.
-
Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L, Dimmock J, Jha A, Das U, Kahan BD, Kirken RA. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol. 2005 Oct 01; 175(7):4236-46.